PROGNYX

Home/The Watchtower/Per Endpoints News, Bristol Myers Squibb claims Phase 2 s…

Editorial illustration for the Prognyx briefing on GPRC5D-directed CAR-T — relapsed/refractory multiple myeloma post-CAR-T

Briefing · From the Watchtower

Per Endpoints News, Bristol Myers Squibb claims Phase 2 success for a GPRC5D-directed CAR-T in multiple myeloma

Endpoints News reports the win frames a GPRC5D CAR-T as a post-relapse option for myeloma patients who progress after CAR-T therapy.

By · Founder, Prognyx ● Sourced to primary records Oncology
In brief — Endpoints News reported on 8 September 2026 that Bristol Myers Squibb claims Phase 2 success for a GPRC5D-directed CAR-T in multiple myeloma, framed as an option for patients who progress after CAR-T therapy. GPRC5D and BCMA are distinct antigens. The BMS-sponsored GPRC5D CAR-T registered on ClinicalTrials.gov is arlocabtagene autoleucel (BMS-986393), which appears in a Phase 2 study (NCT06297226) and a Phase 3 comparison against standard regimens (NCT06615479).

On 8 September 2026, Endpoints News reported that Bristol Myers Squibb claims Phase 2 success for a GPRC5D-directed CAR-T therapy in multiple myeloma [1]. The report frames the result as an option for patients whose disease progresses after CAR-T therapy [2].

The questionThe answer
What did BMS claim?Phase 2 success for a GPRC5D-directed CAR-T in myeloma [1]
Who reported it?Endpoints News, 8 September 2026 — press only [1]
The clinical setting?Post-relapse, after CAR-T therapy [2]
Which asset, per the registry?Prognyx read: arlocabtagene autoleucel, BMS-986393 [5]
Efficacy or safety numbers?Not in the Endpoints reporting Prognyx reviewed [3]
Randomized?Not stated in the reporting reviewed [3]
Confirmatory study running?Phase 3 vs standard regimens, recruiting (NCT06615479) [7]

What happened

Endpoints News, on 8 September 2026, carries the event in this dossier: BMS claims a Phase 2 win for a GPRC5D-directed CAR-T in myeloma [1]. GPRC5D and BCMA are distinct cell-surface antigens. The Endpoints reporting Prognyx reviewed did not carry the asset's name, a trial identifier, response rates, safety readouts, patient numbers or the exact line of therapy [3]. No BMS press release and no SEC filing in this dossier corroborates the claim; the most recent BMS 8-K in context, filed 30 July 2026, does not mention a GPRC5D CAR-T [4].

Prognyx read: the registry points to one candidate for the asset. The BMS-sponsored GPRC5D-directed CAR-T on ClinicalTrials.gov is arlocabtagene autoleucel (BMS-986393), run through Juno Therapeutics, a BMS company [5]. It is registered in a Phase 2 study in relapsed or refractory myeloma (NCT06297226) [5], a Phase 1 of novel combinations with alnuctamab, mezigdomide and iberdomide (NCT06121843) [6], and a Phase 3 comparing BMS-986393 against standard regimens in lenalidomide-exposed patients (NCT06615479) [7]. Tying the Endpoints claim to this specific asset is Prognyx's inference from the registry, not a statement the article makes.

Why it matters

GPRC5D hands a relapsed patient a target their prior therapy did not exhaust. Prognyx read: someone who has already received a BCMA-directed CAR-T, and perhaps a GPRC5D or BCMA bispecific, arrives at the next relapse with few validated mechanisms left, and a CAR-T aimed at GPRC5D is a genetically independent shot. If the Phase 2 claim holds on data, the competitive question is not whether GPRC5D works — talquetamab already carries that target into the clinic [10] — but whether a one-time GPRC5D cell therapy can beat a chronically dosed GPRC5D bispecific antibody on depth and durability of response. Prognyx read: talquetamab's bispecific-antibody modality is accepted class knowledge, not a fact the registry entry in this dossier states. The Endpoints report does not resolve that comparison [3].

Who is exposed

Direct GPRC5D competition, where the registry names the target:

  • Bristol Myers Squibb's own arlocabtagene program keeps moving. A Phase 1 combination study (NCT06121843) [6] and a Phase 3 against standard regimens (NCT06615479) [7] surround the Phase 2 asset. Same asset, same target — the exposure is portfolio sequencing, not rivalry.
  • Johnson & Johnson's talquetamab, which the registry ties to GPRC5D, runs in Phase 2 (NCT04634552) [8] and Phase 1 (NCT03399799) [9], with a dedicated Phase 2 testing prophylaxis for GPRC5D-related oral events (NCT06500884) [10]. Direct on target, different modality — an off-the-shelf bispecific antibody (class knowledge) versus a manufactured cell product. Prognyx read: the oral-toxicity trial signals that GPRC5D's on-target skin and mucosal effects are a known management burden the class carries.
  • Nanjing IASO Biotechnology's CAR-GPRC5D sits in Phase 1 (NCT05759793) [17] — direct on both target and modality, earlier in development.
  • O&D BioTech's O&D-001, which the registry describes as a CAR-T targeting BCMA and GPRC5D, is in Phase 1 (NCT07369895) [16] — a dual-target design engaging both antigens at once.

Same registry pull, target not named in the record reviewed: OriCell Therapeutics' OriCAR-017 (NCT06182696, NCT06271252) [11][12], AstraZeneca's AZD0305 (NCT06106945) [13], Sanofi's SAR446523 (NCT06630806) [18], Jiangsu Simcere's SIM0500 (NCT06375044) [19], Chia Tai Tianqing's TQB2029 (NCT06700395) [20] and Regeneron's REGN17372 with linvoseltamab (NCT07455851) [15] all surfaced in the GPRC5D-tagged registry query, but the intervention text in this dossier does not itself state each one's target. Prognyx did not confirm their mechanism from the record.

What to watch next

  • The BMS Phase 3, arlocabtagene versus standard regimens in lenalidomide-exposed patients, is recruiting (NCT06615479) [7]; it is the confirmatory comparison that would convert a Phase 2 claim into a competitive fact. The dossier does not carry its readout date.
  • A BMS medical-meeting presentation or an SEC 8-K disclosing the Phase 2 efficacy, safety and patient numbers. No such date is set in this dossier [3][4].

What Prognyx could not verify

The event rests on a single Endpoints News headline and summary; no registry record, regulator action or company filing in this dossier states it [1][4]. Open questions: the name or code of the asset behind the claim, which Prognyx has only linked to arlocabtagene autoleucel by inference from the registry [5]; the trial's NCT identifier, patient numbers, response rate, response depth and safety profile; the exact prior-therapy population and line of therapy; whether the study was single-arm or randomized; and whether any BMS release or SEC filing corroborates the Phase 2 result. Until those land, this is a reported claim, not a documented outcome.

Verdict

Prognyx read: threat level moderate and slow-moving. A Phase 2 success claim without disclosed data does not reset the field tonight, but a BMS GPRC5D CAR-T already carrying a running Phase 3 (NCT06615479) [7] is the asset a competing myeloma program should benchmark against. Window to act: until BMS puts the Phase 2 numbers on record at a medical meeting or in a filing — the moment the depth-and-durability contest against talquetamab and the other GPRC5D programs becomes real.

Questions this briefing answers

What exactly did Bristol Myers Squibb claim?

Per Endpoints News on 8 September 2026, BMS claims Phase 2 success for a GPRC5D-directed CAR-T therapy in multiple myeloma. The report frames it as an option for patients who progress after CAR-T therapy.

Which drug is this, and what is the trial?

The Endpoints reporting Prognyx reviewed did not name the asset or a trial. Prognyx read: the BMS-sponsored GPRC5D CAR-T on ClinicalTrials.gov is arlocabtagene autoleucel (BMS-986393), registered in a Phase 2 study (NCT06297226) and a Phase 3 against standard regimens (NCT06615479); linking the claim to it is an inference from the registry.

How is GPRC5D different from the BCMA therapies already used in myeloma?

GPRC5D and BCMA are distinct cell-surface antigens. That makes a GPRC5D CAR-T a genetically independent option for a patient whose prior BCMA-directed therapy has stopped working.

Who competes with BMS on this target?

J&J's talquetamab targets GPRC5D in Phase 1 and 2 (NCT04634552, NCT03399799, NCT06500884). GPRC5D-directed CAR-Ts include Nanjing IASO's CAR-GPRC5D (NCT05759793) and O&D BioTech's BCMA/GPRC5D dual O&D-001 (NCT07369895). Several other registry programs surfaced under the GPRC5D query but do not name their target in the records reviewed.

Sources — every claim traces to the primary record

  1. Endpoints News — BMS claims Phase 2 success for GPRC5D-directed CAR-T (8 Sep 2026)
  2. Endpoints News — same article, post-relapse framing
  3. Endpoints News — article summary lacked asset name, NCT, efficacy/safety and population detail
  4. SEC 8-K — Bristol Myers Squibb Q2 2026 exhibit (no GPRC5D CAR-T reference)
  5. ClinicalTrials.gov NCT06297226 — Arlocabtagene Autoleucel (BMS-986393), GPRC5D CAR-T, Phase 2, recruiting
  6. ClinicalTrials.gov NCT06121843 — BMS-986393 novel combinations, Phase 1, recruiting
  7. ClinicalTrials.gov NCT06615479 — BMS-986393 vs standard regimens, Phase 3, recruiting
  8. ClinicalTrials.gov NCT04634552 — Talquetamab, Phase 2, recruiting (Janssen)
  9. ClinicalTrials.gov NCT03399799 — Talquetamab dose escalation, Phase 1, active not recruiting (Janssen)
  10. ClinicalTrials.gov NCT06500884 — preventive treatments for GPRC5D-related oral events (Talquetamab), Phase 2, recruiting
  11. ClinicalTrials.gov NCT06182696 — OriCAR-017, Phase 1/2, recruiting (OriCell)
  12. ClinicalTrials.gov NCT06271252 — OriCAR-017 RIGEL study, Phase 1, recruiting (OriCell)
  13. ClinicalTrials.gov NCT06106945 — AZD0305 mono/combination, Phase 1/2, recruiting (AstraZeneca)
  14. ClinicalTrials.gov NCT07523555 — adaptive dual-target CAR-T modules, Phase 1/2, recruiting (Beijing Biotech)
  15. ClinicalTrials.gov NCT07455851 — REGN17372 + Linvoseltamab, Phase 1/2, recruiting (Regeneron)
  16. ClinicalTrials.gov NCT07369895 — O&D-001 CAR-T targeting BCMA and GPRC5D, Phase 1, recruiting (O&D BioTech)
  17. ClinicalTrials.gov NCT05759793 — CAR-GPRC5D, Phase 1, recruiting (Nanjing IASO)
  18. ClinicalTrials.gov NCT06630806 — SAR446523, Phase 1, recruiting (Sanofi)
  19. ClinicalTrials.gov NCT06375044 — SIM0500, Phase 1, recruiting (Jiangsu Simcere)
  20. ClinicalTrials.gov NCT06700395 — TQB2029 injection, Phase 1, recruiting (Chia Tai Tianqing)

How this briefing was produced — Drafted and audited by the Prognyx engine against the primary sources cited above, then published automatically for clearing the audit threshold set by Rali Filali. Below that threshold, a briefing is not published. The full method.

Want this on your pipeline?
Get a free sample competitive brief on one of your assets — sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.

Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use.